[HTML][HTML] Drugging the efferocytosis process: concepts and opportunities
P Mehrotra, KS Ravichandran - Nature reviews Drug discovery, 2022 - nature.com
The daily removal of billions of apoptotic cells in the human body via the process of
efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid …
efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid …
[HTML][HTML] Targeting macrophages in hematological malignancies: recent advances and future directions
Emerging evidence indicates that the detection and clearance of cancer cells via
phagocytosis induced by innate immune checkpoints play significant roles in tumor …
phagocytosis induced by innate immune checkpoints play significant roles in tumor …
[HTML][HTML] Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
T Qu, B Li, Y Wang - Biomarker research, 2022 - Springer
Immunotherapy using PD-1 and CTLA4 inhibitors to stimulate T cell immunity has achieved
significant clinical success. However, only a portion of patients benefit from T cell-based …
significant clinical success. However, only a portion of patients benefit from T cell-based …
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach
AN Chamseddine, T Assi, O Mir, S Chouaib - Pharmacology & therapeutics, 2022 - Elsevier
Tumor-associated macrophages (TAM) plasticity and diversity are both essential hallmarks
of the monocyte-macrophage lineage and the tumor-derived inflammation. TAM exemplify …
of the monocyte-macrophage lineage and the tumor-derived inflammation. TAM exemplify …
[HTML][HTML] TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
F Brauneck, B Fischer, M Witt… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Leukemia-associated macrophages (LAMs) represent an important cell
population within the tumor microenvironment, but little is known about the phenotype …
population within the tumor microenvironment, but little is known about the phenotype …
[HTML][HTML] Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
NG Daver, S Iqbal, C Renard, RJ Chan… - Journal of Hematology & …, 2023 - Springer
Background TP53 mutations, which are present in 5% to 10% of patients with acute myeloid
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …
[HTML][HTML] Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies
Interferon gamma (IFNγ) is a critical cytokine known for its diverse roles in immune
regulation, inflammation, and tumor surveillance. However, while IFNγ levels were elevated …
regulation, inflammation, and tumor surveillance. However, while IFNγ levels were elevated …
[HTML][HTML] Molecular targeted therapy and immunotherapy for myelodysplastic syndrome
P Lee, R Yim, Y Yung, HT Chu, PK Yip… - International Journal of …, 2021 - mdpi.com
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder
characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and …
characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and …
Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia
CM Putnam, L Kondeti, MBA Kesler… - Biochemistry and Cell …, 2023 - cdnsciencepub.com
Modulating the immune system to treat diseases, including myeloid malignancies, has
resulted in the development of a multitude of novel therapeutics in recent years …
resulted in the development of a multitude of novel therapeutics in recent years …
Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer
The use of immune checkpoint inhibitors, which activate T cells, is a paradigm shift in the
treatment of non–small cell lung cancer. However, the overall response remains low. To …
treatment of non–small cell lung cancer. However, the overall response remains low. To …